Medicine by Zip Code: How Insurance Bureaucracy Rations Lifesaving Drugs Along Racial and Economic Lines

When Darnell Washington's cardiologist prescribed a newer anticoagulant to manage his atrial fibrillation, neither man anticipated what would come next. Within days, Washington's pharmacy informed him that his insurer had denied coverage. The drug required prior authorization. The appeals process, his insurer explained, could take weeks. In the meantime, he was offered a cheaper, older alternative — one his physician had specifically declined to prescribe because of Washington's documented sensitivity to it. Washington, a 58-year-old Black man living in Memphis, Tennessee, is not an outlier. He is a data point in a pattern that repeats itself, with devastating consistency, across low-income communities and communities of color throughout the United States.

America spends more on healthcare than any other wealthy nation. It also produces some of the most unequal health outcomes among peer economies. The distance between those two facts is not coincidental. It is the product of a deliberate system — one in which the mechanisms designed ostensibly to manage costs have become instruments of rationing, and in which the burden of that rationing falls with disproportionate weight on those who can least afford to bear it.

The Architecture of Denial

Prior authorization — the requirement that a physician obtain insurer approval before a patient can access a prescribed drug — was introduced as a cost-containment measure. In practice, it has become something far more consequential: a bureaucratic checkpoint that delays, dilutes, or entirely prevents access to necessary care.

According to a 2023 survey conducted by the American Medical Association, 94 percent of physicians reported that prior authorization requirements had delayed patient care. Thirty-three percent reported that such delays had led to serious adverse events, including hospitalization. For patients in Medicaid managed care plans — which disproportionately serve low-income Americans and communities of color — denial rates for certain drug classes run significantly higher than for patients in employer-sponsored commercial insurance.

The mechanism is not random. Insurers and pharmacy benefit managers, the largely unregulated intermediaries that negotiate drug pricing between manufacturers and insurers, construct formularies — lists of covered drugs organized into tiers — that structurally disadvantage newer, often more effective medications. Drugs in higher tiers carry steeper cost-sharing requirements. Drugs outside the formulary entirely may require patients to pay full retail price, which, in the American pharmaceutical market, can render even common treatments financially inaccessible.

For a patient with commercial insurance and a high household income, a formulary restriction is an inconvenience. For a patient on a Medicaid plan with a fixed income, it can be a sentence.

Who Bears the Cost of Denial

Research published in the journal Health Affairs found that Black and Latino patients face insurance denials at rates measurably higher than white patients with equivalent diagnoses. The disparity persists even when controlling for income, suggesting that race itself — through the mechanisms of plan type, geographic concentration, and network composition — functions as an independent variable in determining who receives timely medication access.

The consequences compound over time. When a patient with Type 2 diabetes is denied a GLP-1 receptor agonist that their physician has determined is medically appropriate and is instead forced onto an older sulfonylurea, they are not simply receiving an inferior drug. They are being exposed to a higher risk of hypoglycemia, weight gain, and, over the long term, cardiovascular complications. The insurer's short-term cost savings are, in effect, transferred as long-term health costs — paid in suffering, in emergency department visits, in years of life — by the patient.

This is the quiet mathematics of pharmaceutical denial: costs are not eliminated. They are redistributed. And they are redistributed downward, onto the bodies of people who have the least capacity to absorb them.

The Pharmacy Benefit Manager Problem

Central to this system, though largely invisible to the patients it affects, is the pharmacy benefit manager, or PBM. Three firms — CVS Caremark, Express Scripts, and OptumRx — collectively manage pharmacy benefits for the majority of insured Americans. These companies negotiate rebates from drug manufacturers, construct the formularies that determine drug access, and set the reimbursement rates paid to pharmacies. They operate, in most states, with minimal regulatory oversight and no obligation of transparency.

The PBM business model creates a structural incentive that critics argue runs directly counter to patient welfare. Because PBMs historically retain a portion of the rebates they negotiate — a practice known as spread pricing — they have a financial interest in favoring drugs that generate larger rebates, which are not always the drugs that are most clinically appropriate. The result is a formulary system shaped not by medical evidence but by negotiated financial arrangements that occur entirely outside the patient-physician relationship.

For low-income patients and communities of color, who are more likely to be enrolled in Medicaid managed care plans that contract with PBMs, this dynamic carries particular consequence. When a formulary excludes a drug that a physician has determined is medically necessary, the patient's recourse is an appeals process that is time-consuming, technically complex, and frequently unsuccessful — particularly for patients without the resources to navigate it or the advocacy infrastructure to support them.

Preventable Complications, Preventable Deaths

The human cost of this system resists easy quantification, but the available evidence is alarming. A study published in JAMA Internal Medicine found that patients who experienced prior authorization denials for oncology drugs faced measurable delays in treatment initiation that were associated with worse clinical outcomes. In mental health care — a domain in which timely access to the right medication is frequently the difference between stability and crisis — denial rates for newer antidepressants and antipsychotics are among the highest across drug categories.

Patients who lack the time, literacy, or support to pursue appeals often simply go without. Others ration medications — taking half doses, skipping days, or abandoning treatment entirely when cost-sharing requirements exceed what their budgets can sustain. In low-income communities of color, where the cumulative burden of financial precarity intersects with elevated rates of chronic illness, medication non-adherence driven by insurance barriers is not an individual failure of compliance. It is a predictable outcome of a system that has made adherence economically impossible.

Toward Systemic Accountability

The solutions to pharmaceutical access inequality are neither obscure nor technically complex. Federal legislation requiring PBMs to pass the full value of drug rebates through to patients — rather than retaining them as profit — would reduce out-of-pocket costs at the point of sale. Standardized, time-limited prior authorization review periods, with automatic approval defaults when insurer deadlines are missed, would curtail the delays that cause preventable harm. Robust state-level oversight of Medicaid managed care formularies, with enforceable equity benchmarks and public reporting requirements, would create accountability where currently none exists.

Several of these reforms have been proposed. Few have been enacted with the scope or enforcement mechanisms necessary to produce meaningful change. The pharmaceutical and insurance industries together represent among the most powerful lobbying forces in Washington, and their influence over regulatory and legislative outcomes has been proportional to their resources.

What remains, in the absence of systemic reform, is a healthcare system that allocates lifesaving medications not according to medical need but according to the capacity to pay, navigate bureaucracy, and absorb delay. That is not a market inefficiency. It is a moral failure — one that falls, as so many moral failures in this country do, most heavily on those who have already been failed the most.

Restoring fairness in pharmaceutical access requires confronting the institutions that profit from denial and demanding that the right to necessary medication be treated as what it is: a matter of life and death, not a function of zip code.